Innovation Acta S.r.l.

Your voice matters: take 15 minutes to shape #CancerCare 📝 ! GUIDE.MRD, an 🇪🇺 funded project whose DiCE is part of, is gathering insights on integrating circulating tumour DNA (ctDNA) testing for Minimal Residual Disease (MRD) detection into cancer care pathways, providing better outcomes for all. Your feedback is key to making this vision a reality! Whether you're a healthcare professional, caregiver, or advocate, this is your chance to influence how MRD testing can help create a more personalised pathway that addresses the needs of diverse healthcare systems and cancer types. 🗓 Consultation Period: 28 October - 18 November 2024 🔗  https://lnkd.in/ekapimrC 📧 Questions? Reach out at [email protected] #PrecisionOncology #CancerCare #MRD #ctDNA #EUProject #Survey Universitätsklinikum Hamburg Eppendorf Aarhus University UMCG Centre Hospitalier Universitaire de Nice (CHU de Nice) CNIO - Spanish National Cancer Research Centre LungenClinic Grosshansdorf GmbH Karolinska Institutet Illumina Horizon Discovery LGC Clinical Diagnostics The Synergist.org Amgen Bristol Myers Squibb Roche Innovation Acta S.r.l. AstraZeneca Medizinische Universität Graz Centre for Innovation in Medicine Aarhus Universitetshospital Region Stockholm Lung Cancer Europe AbbVie EU Health and Food Safety EU Science, Research and Innovation European Health and Digital Executive Agency (HaDEA) IARC - International Agency for Research on Cancer / World Health Organization Klaus Pantel Ana Martins, Ph.D.

Take part to the public consultation that the Guide.MRD project is launching to help define the ideal healthcare pathway to integrate in clinical practice #ctDNA testing for #MRD detection in solid tumors 👉 Share your insights here https://lnkd.in/deiq85ZC #bmsemployee #guidemrd #ihi #publicprivateprtnership #liquidbiopsy #cancercare Trixia Camacho Stefan Reininghaus-Janßen Yann Guillevic Pieternella [Ellen] de Waal

🚧The current pathway in cancer care has come a long way but still faces challenges—limited early detection, a one-size-fits-all approach to treatment, and the need for better communication with patients. There are real opportunities to improve how we detect, monitor, and treat cancer. We’re exploring how MRD testing can help create a more personalized, patient-centered pathway that improves outcomes and quality of life. We want to hear your thoughts. 📣 Share your experiences in our public consultation survey and help us shape a better future for #cancercare. ⏩https://lnkd.in/dcHWdzaA #liquidbiopsy #precisionmedicine _____ Universitätsklinikum Hamburg Eppendorf, Aarhus University, UMCG, Centre Hospitalier Universitaire de Nice (CHU de Nice), CNIO - Spanish National Cancer Research Centre, LungenClinic Grosshansdorf GmbH, Karolinska Institutet, Illumina, Horizon Discovery, LGC Clinical Diagnostics, The Synergist.org, Digestive Cancers Europe, Amgen, Bristol Myers Squibb, Roche, Innovation Acta S.r.l., AstraZeneca, Medizinische Universität Graz, Centre for Innovation in Medicine, Aarhus Universitetshospital, Region Stockholm, Lung Cancer Europe, AbbVie _____ GUIDE.MRD Coordinator: Klaus Pantel _____ This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

The current cancer care pathway has its challenges, impacting patients and the healthcare system alike. 🩸By using ctDNA-based liquid biopsy for fast, accurate detection of cancer relapse, we’re aiming to: • Reduce unnecessary interventions and side effects • Improve health outcomes and quality of life for people living with cancer • Alleviate the psychological stress patients face in their treatment journey • Lighten the socio-economic burden on society as a whole 🧩By creating standards and harmonization in the field, our goal is to improve the quality and reliability of testing—laying the foundation for more precise, patient-centered care. Your perspective is crucial to shaping this future. Share your insights ⏩https://lnkd.in/dcHWdzaA #CancerCare #liquidbiopsy #SocietalImpact _____ Universitätsklinikum Hamburg Eppendorf, Aarhus University, UMCG, Centre Hospitalier Universitaire de Nice (CHU de Nice), CNIO - Spanish National Cancer Research Centre, LungenClinic Grosshansdorf GmbH, Karolinska Institutet, Illumina, Horizon Discovery, LGC Clinical Diagnostics, The Synergist.org, Digestive Cancers Europe, Amgen, Bristol Myers Squibb, Roche, Innovation Acta S.r.l., AstraZeneca, Medizinische Universität Graz, Centre for Innovation in Medicine, Aarhus Universitetshospital, Region Stockholm, Lung Cancer Europe, AbbVie _____ GUIDE.MRD Coordinator: Klaus Pantel _____ This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

💬 Have your say! Our GUIDE.MRD project is running a consultation on how best to integrate into healthcare tests for circulating tumour DNA, to detect minimal residual disease in #cancer. 👉 They want to hear from people with cancer (especially non-metastatic lung, pancreatic & colorectal cancer), cancer survivors, family members, healthcare providers and others. Deadline: 18 November #MissionCancer #HorizonEU #IHITransformingHealth

Bridging the Gap in Cancer Care! One key challenge healthcare professionals have shared is the need for improved communication and shared decision-making with patients throughout their treatment journey. Ensuring patients are informed, comfortable with their treatment options, and involved in decision-making can truly transform care. We’re working towards a future where MRD testing is part of a patient-centered care pathway—and we need your help to make it happen. Your input could make a real difference. Make your voice heard ⏩ https://lnkd.in/dcHWdzaA #PrecisionOncology #CancerCare #MRD #ctDNA _____ Universitätsklinikum Hamburg Eppendorf, Aarhus University, UMCG, Centre Hospitalier Universitaire de Nice (CHU de Nice), CNIO - Spanish National Cancer Research Centre, LungenClinic Grosshansdorf GmbH, Karolinska Institutet, Illumina, Horizon Discovery, LGC Clinical Diagnostics, The Synergist.org, Digestive Cancers Europe, Amgen, Bristol Myers Squibb, Roche, Innovation Acta S.r.l., AstraZeneca, Medizinische Universität Graz, Centre for Innovation in Medicine, Aarhus Universitetshospital, Region Stockholm, Lung Cancer Europe, AbbVie _____ GUIDE.MRD Coordinator: Klaus Pantel _____ This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Shaping the Future of Cancer Care Together We're committed to improving #cancercare by finding and validating the most reliable ctDNA-based tests for detecting minimal residual disease (MRD). But we know we can't do it alone. Soon, we'll be reaching out to hear 𝙮𝙤𝙪𝙧 experiences and insights. 💪Your voice matters, and together, we can work towards more personalized, effective cancer care. 📣Stay tuned—we’re looking forward to starting the conversation! Join our newsletter ⏩ https://lnkd.in/d5ReJVHY #PrecisionOncology #CancerCare #MRD #ctDNA _____ Universitätsklinikum Hamburg Eppendorf, Aarhus University, UMCG, Centre Hospitalier Universitaire de Nice (CHU de Nice), CNIO - Spanish National Cancer Research Centre, LungenClinic Grosshansdorf GmbH, Karolinska Institutet, Illumina, Horizon Discovery, LGC Clinical Diagnostics, The Synergist.org, Digestive Cancers Europe, Amgen, Bristol Myers Squibb, Roche, Innovation Acta S.r.l., AstraZeneca, Medizinische Universität Graz, Centre for Innovation in Medicine, Aarhus Universitetshospital, Region Stockholm, Lung Cancer Europe, AbbVie _____ GUIDE.MRD Coordinator: Klaus Pantel _____ This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

💭Imagine a Future Where… ✅Every Cancer Patient’s Journey is Personal. ✅MRD testing helps detect cancer relapse early, and treatment is tailored to each patient's specific needs. ✅ Precise insights into the disease guide every decision, and each step is designed to improve outcomes and quality of life. This is the vision we're working towards at GUIDE.MRD. Now, we want to hear from you. 📣We’re launching a public consultation to gather feedback from all voices—patients, healthcare professionals, and advocates. Your experiences, insights, and perspectives are invaluable as we work toward making MRD testing a standard part of #cancercare, providing better outcomes for all. Join us and help transform cancer care for the better ⏩https://lnkd.in/dcHWdzaA. #PrecisionOncology #CancerCare #MRD #ctDNA _____ Universitätsklinikum Hamburg Eppendorf, Aarhus University, UMCG, Centre Hospitalier Universitaire de Nice (CHU de Nice), CNIO - Spanish National Cancer Research Centre, LungenClinic Grosshansdorf GmbH, Karolinska Institutet, Illumina, Horizon Discovery, LGC Clinical Diagnostics, The Synergist.org, Digestive Cancers Europe, Amgen, Bristol Myers Squibb, Roche, Innovation Acta S.r.l., AstraZeneca, Medizinische Universität Graz, Centre for Innovation in Medicine, Aarhus Universitetshospital, Region Stockholm, Lung Cancer Europe, AbbVie _____ GUIDE.MRD Coordinator: Klaus Pantel _____ This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe, and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

ReSHAPE Final Workshop on Next-Generation Treg Development and Biomarker Platforms - Berlin 📍 As partner of ReSHAPE consortium and organizer of this event, we are excited to announce the ReSHAPE Final Workshop on Next-Generation Treg Development, Product Characterization, and Biomarker Platform & Improvement of In Vivo Engraftment of Adoptively Transferred Tregs, which will take place on December 5th in Berlin. This workshop will showcase the research achievements of the ReSHAPE Project, with presentations by Prof. Petra Reinke, the Project Coordinator, and consortium partners. We will also host talks by renowned external experts and opinion leaders in adoptive Treg therapy, who will share their latest findings. This event is a valuable opportunity for the scientific community to engage with cutting-edge developments in next-generation Treg research. 📣 The event is open to external participants. ✒ If you are interested to join please register to the event filling the form at this link https://lnkd.in/dQTE_cjA  by November 4th 2024. For more information about ReSHAPE visit our website: https://lnkd.in/dzzYUvjf https://lnkd.in/dwbsTAXp

Participating in medical research helps shape the future of healthcare. When you volunteer in clinical research, your contribution can improve diagnostic tools and treatments. We in GUIDE.MRD have participating centers for our observational clinical studies across Europe. It's essential to understand your rights - such as receiving full information about the study, knowing how your data will be handled, and the freedom to withdraw at any time without affecting your care. Being informed ensures you make a confident decision. Learn more about what to expect and how your involvement makes a difference ⏩https://lnkd.in/eFSRsrcR #CancerCare #liquidbiopsy #precisionmedicine _____ Universitätsklinikum Hamburg Eppendorf, Aarhus University, UMCG, Centre Hospitalier Universitaire de Nice (CHU de Nice), CNIO - Spanish National Cancer Research Centre, LungenClinic Grosshansdorf GmbH, Karolinska Institutet, Illumina, Horizon Discovery, LGC Clinical Diagnostics, The Synergist.org, Digestive Cancers Europe, Amgen, Bristol Myers Squibb, Roche, Innovation Acta S.r.l., AstraZeneca, Medizinische Universität Graz, Centre for Innovation in Medicine, Aarhus Universitetshospital, Region Stockholm, Lung Cancer Europe, AbbVie _____ CC Klaus Pantel _____ This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.